The House Ways and Means Committee today held a hearing on the Department of Health and Human Services’ fiscal year 2019 budget request, at which HHS Secretary Alex Azar testified. The non-binding budget request proposes hundreds of billions of dollars in reductions to Medicare and Medicaid over 10 years, as well as a number of provisions related to drug pricing, opioids and other health-related issues. In his opening remarks, Chairman Kevin Brady (R-TX) said the committee has developed “consensus solutions” on health care and is “eager to work with the Trump administration to build on them wherever possible,” including “taking action to reduce the cost of prescription drugs.” Committee members also urged aggressive action to address the opioid crisis, and Democrats criticized the proposed cuts to Medicare and Medicaid. Ranking Member Richard Neal (D-MA) noted that the budget request “cuts more than $200 billion in payments to hospitals,” threatening additional hospital closures and the jobs they provide. Reps. Terri Sewell (D-AL) and Tom Rice (R-SC) also expressed concern about rural hospital closures. “We have consistently asked rural hospitals to do more with less,” Sewell said. “As a result, 83 rural hospitals have closed since 2010 across the country.”

Related News Articles

Headline
An analysis by KFF released last week found that in 2022, Medicare spent 27% ($2,585) more, on average, for individuals covered by Traditional Medicare after…
Headline
A House Dear Colleague letter calling on House leadership to address scheduled Medicaid Disproportionate Share Hospital payment cuts received signatures from…
Headline
The AHA Dec. 9 said it supports a potential Medicare $2 Drug List Model, where people enrolled in a Part D plan would have access to certain prescription drugs…
Headline
In comments Dec. 9 to the Medicare Payment Advisory Commission, the AHA shared its views on physician fee schedule payments, advanced alternative payment model…
Headline
The Centers for Medicare & Medicaid Services Dec. 4 announced that drug manufacturers bluebird bio, inc. (manufacturer of Lyfgenia) and Vertex…
Headline
The Centers for Medicare & Medicaid Services Nov. 26 proposed changes to the Medicare Advantage and prescription drug programs for contract year 2026.…